IndiaUSEM drives earnings

Company
11 Mar 2024
5 Min read 
  • Zydus LifeSciences reported better-than-expected performance for 3QFY24.
  •  The company exhibited strong execution in the domestic formulation and emerging markets.
  •  Earnings estimate raised by 6%/7% for FY24/FY25.
  •  Valued at 21x 12M forward earnings with a price target of INR820.
  •  Building a robust product pipeline in innovative and branded generics.
  •  Neutral stance on the stock due to limited upside from current levels.
Login / Open Demat Account to read the report

Never Miss Out on Hot Market Updates

Get exclusive market news delivered to your inbox - on priority